Sovaldi (sofosbuvir)–based hepatitis C virus (HCV) regimens boast high cure rates in real-world practice among those coinfected with HIV. Researchers analyzed data on HIV/HCV-coinfected participants in the French nationwide ANRS C013 HEPAVIH cohort, looking at 171 people, from 23 clinics, who started HCV treatment before March 1, 2015 if they were treated for 12 weeks or before December 1, 2014 if they were treated for 24 weeks. Results were presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

Seventy-three percent of the cohort had cirrhosis; 70 percent had failed a previous hep C cure attempt. Sixty-two percent of the cohort had genotype 1 of hep C; 2 percent had genotype 2; 14 percent had genotype 3; and 22 percent had genotype 4.

Ninety-eight percent of the members of the cohort were on treatment for HIV.

Overall, 92 percent of the participants achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure), including 92 percent of those with cirrhosis and 91 percent of those without cirrhosis.

A total of 117 of the partcipants (68 percent) took Sovaldi and Daklinza (daclatasvir), with or without ribavirin; 93 percent were cured. Fifteen people (9 percent) took Harvoni (ledipasvir/sofosbuvir); 87 percent were cured. Twenty-six people (15 percent) took Sovaldi and ribavirin; 88 percent were cured. Thirteen people (8 percent) took Sovaldi and Olysio (simeprevir), with or without ribavirin; 92 percent were cured.

Among the 90 cirrhotic individuals who were treated without ribavirin, cure rates for those treated for 12 or 24 weeks were a respective 91 percent and 93 percent. Among cirrhotic individuals who did take ribavirin, the respective cure rates after 12 or 24 weeks of treatment were 83 percent and 93 percent.

Seventy-one percent of those who failed treatment had cirrhosis.

To read the conference abstract, click here.